268.93
2.35%
+6.18
AMGEN Inc. stock is currently priced at $268.93, with a 24-hour trading volume of 3.29M.
It has seen a +2.35% increased in the last 24 hours and a -1.03% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $263.8 pivot point. If it approaches the $268.3 resistance level, significant changes may occur.
AMGEN Inc. Stock (AMGN) Financials Data
AMGEN Inc. (AMGN) Revenue 2024
AMGN reported a revenue (TTM) of $28.19 billion for the quarter ending December 31, 2023, a +7.09% rise year-over-year.
AMGEN Inc. (AMGN) Net Income 2024
AMGN net income (TTM) was $6.72 billion for the quarter ending December 31, 2023, a +2.52% increase year-over-year.
AMGEN Inc. (AMGN) Cash Flow 2024
AMGN recorded a free cash flow (TTM) of $7.36 billion for the quarter ending December 31, 2023, a -16.23% decrease year-over-year.
AMGEN Inc. (AMGN) Earnings per Share 2024
AMGN earnings per share (TTM) was $12.49 for the quarter ending December 31, 2023, a +3.14% growth year-over-year.
AMGEN Inc. Stock (AMGN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Grygiel Nancy A. | SVP & CCO |
Dec 04 '23 |
Sale |
273.03 |
2,096 |
572,276 |
10,874 |
Graham Jonathan P | EVP, Gen. Counsel & Secy. |
Nov 08 '23 |
Sale |
272.81 |
10,000 |
2,728,136 |
28,078 |
AMGEN INC | 10% Owner |
Sep 19 '23 |
Buy |
17.00 |
1,764,705 |
29,999,985 |
35,368,653 |
Gordon Murdo | EVP, Global Commercial Ops |
Aug 10 '23 |
Sale |
262.43 |
9,558 |
2,508,306 |
44,308 |
AMGEN Inc. Stock (AMGN) Latest News
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Zacks Investment Research
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
Zacks Investment Research
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Benzinga
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
Can This High-Yield Dividend Stock Keep Beating the S&P 500?
The Motley Fool
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
The Motley Fool
About AMGEN Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Cap:
|
Volume (24h):